IVX.AU · Invion Limited

-

Please sign in to comment on IVX.AU

1 Comment

Admin

4 years, 1 month ago

Invion Limited is currently in a long term uptrend where the price is trading 29.5% above its 200 day moving average.

From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.3.

Invion Limited's total revenue sank by 32.9% to $1M since the same quarter in the previous year.

Its net income has increased by 27.8% to $-852K since the same quarter in the previous year.

Finally, its free cash flow grew by 85.0% to $-49K since the same quarter in the previous year.

Based on the above factors, Invion Limited gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000IVX4
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Target Price	0.11
PE Ratio	None
Market Cap	8M
Beta	0.78
Dividend Yield	None

ABOUT

Invion Limited

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

IVX.AU · Invion Limited

-

Invion Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Invion Limited using a moving average strategy